AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients

NEXT STORY
Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting
PREV STORY
Guardant Health to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immune Design and Gritstone Oncology Announce Clinical Collaboration for Neoantigen Cancer Immunotherapy

SEATTLE and SOUTH SAN FRANCISCO, Calif. and EMERYVILLE Calif,, May 09, 2016 (GLOBE NEWSWIRE) ...

author_avatar
NASDAQ Market News

ProLynx announces PLX039, a hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist

SAN FRANCISCO, June 12, 2017 (GLOBE NEWSWIRE) -- In a late-breaking abstract at the ...

author_avatar
NASDAQ Market News

Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment

author_avatar
NASDAQ Market News